A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction We previously reported data on the safety, tolerability, and recommended phase II dose of obatoclax mesylate in conjunction with topotecan in patients with advanced solid tumor malignancies. Preliminary efficacy data suggested activity in patients with recurrent small cell lung cancer (SCLC). Based on these data, we performed a phase II study of obatoclax mesylate plus topotecan in patients with relapsed SCLC to assess efficacy. Methods This was an open-label, single-arm, phase II extension of obatoclax mesylate plus topotecan in patients with relapsed SCLC. Obatoclax mesylate was given intravenously (IV) at a dose of 14 mg/m2 on days 1 and 3 with IV topotecan at 1.25 mg/m2 on days 1–5 of an every 3-week cycle. The primary end-point of this study was overall response rate. Results Nine patients with recurrent SCLC were enrolled into the first stage of the study. Patients received a median of 2 cycles of treatment. All patients were evaluable for the primary end-point of overall response. There were no partial or complete responses. Five patients (56%) had stable disease. The remaining four patients (44%) developed progressive disease. The most common grade 3 or 4 adverse events included thrombocytopenia (22%), anemia (11%), neutropenia (11%), and ataxia (11%). Conclusion Obatoclax mesylate added to topotecan does not exceed the historic response rate seen with topotecan alone in patients with relapsed SCLC following the first-line platinum-based therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schimmer, A. D., O'Brien, S., Kantarjian, H., Brandwein, J., Cheson, B. D., Minden, M. D., Yee, K., Ravandi, F., Giles, F., Schuh, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0999 · Cited by 192
Hwang, J. J., Kuruvilla, J., Mendelson, D., Pishvaian, M. J., Deeken, J. F., Siu, L. L., Berger, M. S., Viallet, J., & Marshall, J. L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0822 · Cited by 109
Cited by
Gay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lu, W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.014 · Cited by 962
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Targeting protein–protein interactions as an anticancer strategy
Ivanov, A. A., Khuri, F. R., & Fu, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.007 · Cited by 401
“Another oral BH3-mimetic, Obatoclax (GS-01570), discovered by screening natural product libraries, is currently in Phase II clinical trials in patients with small cell lung cancer [18, 74, 75].”
BackgroundWhy do BCL-2 inhibitors work and where should we use them in the clinic?
Montero, J., & Letai, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.183 · Cited by 327
Metadata
- Authors
- Paik, P. K., Rudin, C. M., Pietanza, M. C., Brown, A., Rizvi, N. A., Takebe, N., Travis, W., James, L., Ginsberg, M. S., Juergens, R., Markus, S., Tyson, L., Subzwari, S., Kris, M. G., & Krug, L. M.
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 74
- Issue
- 3
- Pages
- 481-485
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2096495293
- Cited by
- 98
- References
- 2
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. https://app.cochat.ai/papers/10.1016/j.lungcan.2011.05.005
- The paper
- Paik, P. K., Rudin, C. M., Pietanza, M. C., Brown, A., Rizvi, N. A., Takebe, N., Travis, W., James, L., Ginsberg, M. S., Juergens, R., Markus, S., Tyson, L., Subzwari, S., Kris, M. G., & Krug, L. M. (2011). A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. https://doi.org/10.1016/j.lungcan.2011.05.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.